Pomalidomide

Description

Pomalidomide is used along with dexamethasone to treat a type of blood cancer known as multiple myeloma in patients who have already received at least 2 therapies including lenalidomide and a proteasome inhibitor, and has not improved during or within 60 days of completion of the last therapy. This medicine is not recommended for use in patients below 18 years of age.

Side effects

Major & minor side effects for Pomalidomide

  • Blood in urine and stools
  • Chest tightness
  • Chills
  • Cough
  • Dry mouth
  • Dizziness and Drowsiness
  • Difficulty in breathing
  • Headache
  • Loss of appetite
  • Lower back or side pain
  • Nausea and vomiting
  • Unusual weight gain or loss
  • Stomach pain
  • Fainting

Uses of Pomalidomide

What is it prescribed for?

  • Multiple Myeloma
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time required for this medicine to show its action is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women due to the increased risk of serious adverse effects on the unborn baby.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Pomalidomide or any other inactive ingredients present along with this medicine.

Pregnancy

This medicine is not recommended for use in pregnant women due to the increased risk of harmful effects on the unborn baby.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women due to the increased risk of serious adverse effects on the unborn baby.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
General warnings

Use in Children

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

Driving or operating machinery

This medicine may cause symptoms such as drowsiness, dizziness, tiredness, muscle weakness, etc. in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Hematologic Toxicities

This medicine should be used with caution in patients suffering from hematological toxicities due to the increased risk of worsening of the patient's condition. It is recommended to monitor complete blood picture weekly for the first eight weeks and monthly thereafter while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Neuropathy

This medicine should be used with extreme caution in patients with or at risk for neuropathy due to the increased risk of worsening of the patient's condition. Report any unusual symptoms to the doctor immediately. Close monitoring of the clinical condition, corrective measures, appropriate patient/caregiver counseling, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Smoking

Smoking is not recommended during the treatment with this medicine, since it may alter the desired effects of Pomalidomide. Report any unusual symptoms to the doctor on priority.

Thromboembolism

This medicine may cause venous and arterial thromboembolic events and should be used with extreme caution in patients with prior thrombosis or any known risk factors. Prophylactic antithrombotic measures are recommended and the choice of regimen should be based on the assessment of the patient's underlying risk factors. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Tumor lysis syndrome (TLS)

This medicine may cause a condition called Tumor lysis syndrome (TLS) an abnormality that occurs as a complication of cancer therapy, where a large number of tumor cells are killed and released into the bloodstream. Report signs and symptoms of tumor lysis syndrome such as diarrhea, muscle cramps, weakness, numbness, nausea, vomiting, etc. to the doctor immediately. Close monitoring of the clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Live attenuated vaccines and related products

Deferiprone

Infliximab

Adalimumab

Clozapine

Disease interactions

Renal impairment

This medicine should be used with caution in patients suffering from kidney diseases due to the increased risk of severe adverse effects. Close monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Hepatic impairment

This medicine should be used with caution in patients suffering from liver diseases due to the increased risk of severe adverse effects. Close monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
Take this medicine exactly as instructed by the doctor. Do not take in larger or smaller amounts than prescribed. Report any unusual symptoms to the doctor immediately. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken on an empty stomach

To be taken as instructed by doctor

May cause sleepiness

How it works
It helps the bone marrow to produce normal blood cells and kills abnormal cells in the bone marrow.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Miscellaneous antineoplastics, Other immunosuppressants

Schedule

Schedule H

Pomalong Capsules [Internet]. CiplaMed. 2019 [cited 1 February 2019]. Available from:

https://ciplamed.com/content/pomalong-capsules

[Internet]. Accessdata.fda.gov. 2018 [cited 14 December 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf

Pomalidomide: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2018 [cited 14 December 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a613030.html

Pomalidomide - DrugBank [Internet]. Drugbank.ca. 2018 [cited 14 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB08910

[Internet]. Medicines.org.uk. 2018 [cited 14 December 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.1262.pdf

[Internet]. 2018 [cited 14 December 2018]. Available from:

https://medsafe.govt.nz/Consumers/CMI/p/pomalyst.pdf

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 1 Feb 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.